Portal Diabetes

What Portal Diabetes does

Portal Diabetes, Inc. is a privately held, Delaware-incorporated medical device company headquartered in Westfield, Indiana, developing an implantable artificial pancreas system for people with Type 1 diabetes (T1D). The company's core product, the Portal Pump, is an implantable insulin pump designed to deliver insulin directly to the intraperitoneal space near the liver, enabling rapid physiologic uptake and a fully automated closed-loop insulin delivery system. The system is paired with Portal Insulin, a proprietary temperature-stable insulin formulation that does not require refrigeration, and integrates with continuous glucose monitor (CGM) technology via a control algorithm that automates dosing without requiring carbohydrate counts, meal announcements, exercise announcements, or nighttime glucose management.

The proposed device is implanted during an outpatient procedure, remains in the body for 5-7 years, and is refilled with insulin on a weeks-to-months cadence. The company targets a large unmet need: only ~20% of adults with T1D currently achieve ADA glycemic targets, and current subcutaneous therapy imposes an estimated 2,000+ annual management tasks per patient. Portal Diabetes claims its system could reduce this to 5-40 annual tasks while targeting approximately 90% time-in-range.

Commercially, Portal Diabetes is pre-revenue: the Portal Pump and Portal Insulin are in research and development, are not FDA-approved, and are not available for sale in any country. The company received FDA Breakthrough Device Designation in February 2026, initiated a Phase 1 study of Portal Insulin in February 2026 (with first two patients dosed in San Diego), and plans to begin clinical trials for the combination system in Q4 2027. The company has not disclosed funding rounds, pricing, distribution channels, or go-to-market details, and operates with a small executive team of six experienced medical-device professionals.

Name

Portal Diabetes

Legal name

Portal Diabetes, Inc.

Website

https://portaldiabetes.com

Company type

Private

Operating status

Operating

Short description

Portal Diabetes is a private, clinical-stage medical device company developing an implantable artificial pancreas — the Portal Pump with proprietary temperature-stable insulin and CGM integration — to fully automate insulin delivery for people with Type 1 diabetes in the United States.

Ownership category

akta.pro rank

Product category

Implantable Insulin Delivery Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)

akta.pro secondary industry

Insulin Pumps & Patch Pumps (HLAHAIAG)

Keywords

• Implantable insulin pump
• Artificial pancreas system
• Type 1 diabetes device
• Automated insulin delivery
• Temperature-stable insulin

Headquarters

HQ city

Westfield

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Core offering

Portal Diabetes is developing an implantable insulin pump system (the Portal Pump) intended to function as the first artificial pancreas, delivering insulin directly to the intraperitoneal space for rapid uptake by the liver and enabling fully automated insulin delivery for people with type 1 diabetes. The offering pairs the implantable pump with a proprietary temperature-stable insulin formulation (Portal Insulin) and integrates with continuous glucose monitoring (CGM) technology. The product is in research and development and is not yet FDA-approved or commercially available.

Product overview

Portal Diabetes is developing an integrated artificial pancreas system consisting of two primary components: the Portal Pump (an implantable insulin pump) and Portal Insulin (a proprietary temperature-stable insulin formulation). These products work together as a closed-loop system that integrates with continuous glucose monitoring technology to provide fully automated insulin delivery, functionally curing type 1 diabetes by restoring normal pancreatic function.

Differentiator

Problem solved

Functional benefit

Products and services

• Portal Pump An implantable insulin pump designed to function as an artificial pancreas for people with type 1 diabetes. The device delivers insulin directly to the peritoneal space (near the liver), enabling fully automated insulin delivery via a basic control algorithm, and is implanted during an outpatient procedure with a 5-7 year device duration.
• Portal Insulin A proprietary temperature-stable insulin formulation designed for use with the Portal Pump system. The insulin maintains stability without refrigeration, simplifying storage and handling for patients, and is currently in Phase 1 clinical trials.

Quantifiable outcome

• 90% average time in range
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Beta Bionics: Beta Bionics developed the iLet bionic pancreas, an automated insulin delivery system designed to require minimal patient input. It is the closest pure AID-platform competitor to Portal Diabetes and is also pursuing meal-announcement-free automation, directly targeting Portal's core differentiator.
• Insulet: Insulet's Omnipod is the leading tubeless patch pump and has been advancing its Omnipod 5 AID system with CGM integration. It serves the same T1D patient population and competes on automation, wearability, and management burden — directly overlapping Portal's value proposition.
• Tandem Diabetes Care: Tandem's t:slim X2 with Control-IQ is a leading automated insulin delivery system combining a tubed pump with CGM. It targets the same Type 1 diabetes population as Portal Diabetes and competes head-to-head on AID outcomes, ease of use, and time-in-range — though with a subcutaneous rather than intraperitoneal approach.

Emerging players

• MannKind Corporation: MannKind develops and markets Afrezza, an inhaled insulin, and has been working on next-generation insulin formulations. It overlaps with Portal Diabetes on the insulin formulation and alternative-delivery side, and represents a comparable alternative-route-of-administration strategy.
• Bigfoot Biomedical: Bigfoot is developing connected insulin pen and pump systems with CGM integration aimed at simplifying T1D management. It targets the same automation and burden-reduction use cases as Portal Diabetes but with a non-implantable delivery model.

Broad incumbents

• Dexcom: Dexcom is the leading continuous glucose monitor manufacturer and is a critical ecosystem component for any AID system, including the Portal Pump. While not a direct pump competitor, it is the CGM partner-of-choice for the AID category Portal is entering.
• Medtronic: Medtronic is the established leader in insulin pump therapy (MiniMed) and is actively advancing its automated insulin delivery systems with CGM integration. It is the dominant incumbent in the category Portal Diabetes is targeting and the most direct comparator for any new insulin pump platform entering the U.S. market.
• Abbott Diabetes Care: Abbott's FreeStyle Libre is the dominant CGM platform globally and integrates with multiple insulin delivery systems. As a CGM ecosystem incumbent and growing presence in automated insulin delivery, Abbott is a key infrastructure peer for any AID-platform entrant including Portal Diabetes.

Peers

• Nalu Medical:

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Portal Diabetes